New drug tested in people with liver problems

NCT ID NCT07324616

First seen Jan 09, 2026 · Last updated May 16, 2026 · Updated 15 times

Summary

This early-stage study looks at how a single dose of the experimental drug EDG-7500 is processed by the body in people with mild or moderate liver impairment compared to those with normal liver function. About 32 adults will participate to measure drug levels in the blood and check for side effects. The goal is to understand if liver function affects how the drug works, not to treat any condition.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT (HI) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Orlando Clinical Research Center

    RECRUITING

    Orlando, Florida, 32809, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The University of Miami Division of Clinical Pharmacology

    RECRUITING

    Miami, Florida, 33136, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.